Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in ...

The FDA has approved Mounjaro to reduce cardiovascular risk in people with type 2 diabetes after a major trial found it ...

Ozempic (semaglutide) and Trulicity (dulaglutide) are brand-name subcutaneous injections. They’re both prescribed for adults with type 2 diabetes who may or may not have certain cardiovascular ...

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity ™ 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza ® 0.9 mg after ...

Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

Novo Nordisk and Eli Lilly are locked in a tough fight, both vying for the top spot in the GLP-1 diabetes treatment class. On strategy they’ve both pursued is increasing the dosing of their existing ...